ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers

NCT ID: NCT01875926

Last Updated: 2018-07-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2013-10-31

Brief Summary

The overall aims of the study are:

• To provide additional information on the pharmacokinetics of ALX-0171 by measuring (i) local (bronchoalveolar lavage fluid (BALF)) and systemic (plasma) concentrations of ALX-0171 after oral inhalation, and (ii) systemic (plasma) and urine concentrations after intravenous administration.
• To further determine the safety and local and systemic tolerability of ALX-0171.
• To further evaluate local (induced sputum) and/or systemic (serum) immunogenicity of ALX-0171, by analysing the potential occurrence of anti-drug antibodies (ADA).

Conditions

Healthy; RSV Infection

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ALX-0171 Oral Inhalation - Single Dose (SD)

Group Type: EXPERIMENTAL

ALX-0171

Intervention Type: BIOLOGICAL

single dose of 200 mg ALX-0171 via oral inhalation

ALX-0171 Oral Inhalation - Multiple Dose (MD)

Group Type: EXPERIMENTAL

ALX-0171

Intervention Type: BIOLOGICAL

repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days

ALX-0171 Intravenous (IV)

Group Type: EXPERIMENTAL

ALX-0171

Intervention Type: BIOLOGICAL

Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration

Interventions

ALX-0171

single dose of 200 mg ALX-0171 via oral inhalation

Intervention Type: BIOLOGICAL

ALX-0171

repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days

Intervention Type: BIOLOGICAL

ALX-0171

Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Non-smoking healthy male volunteers, (18-55 years, extremes included).

2. Good health condition, as determined by medical history, physical examination and clinical laboratory testing

3. Body mass index (BMI) within normal range: 18.0 ≤ BMI < 30.0 (kg/m2)

4. Haematology and chemistry parameters within normal range, or showing no clinically relevant deviations (as judged by the Investigator)

5. Heart rate and/or blood pressure within normal range (as judged by the Investigator)

6. Electrocardiogram (ECG) within normal range, or showing no clinically relevant deviations (as judged by the Investigator)

7. Negative urine test for selected drugs of abuse at screening

8. Negative alcohol breath test upon check-in at study unit

9. Negative hepatitis panel (including hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibodies (anti-HCV)), and negative human immunodeficiency virus (HIV) antibody screens

10. Willingness to consent to using an effective contraceptive method (by using 2 methods of contraception in combination with a female partner: at least 1 of the contraception methods must be a barrier contraception method, e.g., condom) during the study and for at least 3 months after last study drug administration

11. Ability to comprehend and willingness to sign an Informed Consent Form (ICF)

For oral inhalation only:

12. Lung function test which shows a Forced Expiratory Volume in 1 second (FEV1) ≥ 90% of predicted value

13. Ability to retro-breathe with nebulizer

14. Height between 170 and 190 cm (extremes included)

15. Ability to produce a sufficient amount of induced sputum (at least 400 μL containing visual sputum plugs) to assess immunogenicity

Exclusion Criteria

1. Current smokers, or ex-smokers abstinent from tobacco for less than one year, or a history of smoking more than 10 packs a year

2. Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing

3. Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in the absence of febrile episodes, in the last 14 days prior to dosing

4. History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism or excretion of drugs

5. Malignancy, or prior malignancy, with a disease-free interval of < 5 years after diagnosis and intervention, except basal cell carcinoma (treated curatively)

6. Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis.

7. History of hypersensitivity or allergies to any drug compound, including constituents of ALX-0171

8. History of previous administration of ALX-0171, or any other inhaled biologic or drug targeting the Respiratory Syncytial Virus (RSV) F protein. In any other case of use of biologics: at least 6 months before administration of first study medication, or the time of duration of the pharmacodynamic effect, or 10 times the half-life of the respective drug, whatever is longer

9. Receipt of any investigational drug within 60 days prior to dosing

10. Intake of prescribed or over-the-counter medication within 14 days prior to dosing (≤ 3 g/day paracetamol is allowed)

11. History or presence of alcohol or drug abuse

12. Blood donation (> 500 mL) or a comparable blood loss within three months prior to dosing

13. Planned donation of germ cells, blood, organs, bone marrow during the course of the study or within 6 months thereafter

14. Any other condition or prior therapy which, in the opinion of the Investigator, would make the subject unsuitable for this study

15. Vulnerable subjects (e.g., persons kept in detention)

For oral inhalation only:

16. History or presence of atopy or any condition associated with airway hyperresponsiveness (e.g., allergic or non-allergic asthma, chronic obstructive pulmonary disease (COPD))

17. FEV1 drop of > 10% after inhalation of 4 mL of ALX-0171 placebo (measured at 5 min after the end of inhalation)

18. Contra-indication for sputum induction, such as (but not limited to) recent eye surgery, recent fractured ribs and recent (or history of) pneumothorax

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Ablynx, a Sanofi company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Steven De Bruyn, MD

Role: STUDY_DIRECTOR

Ablynx NV

Locations

Antwerp, , Belgium

Countries

Belgium

Other Identifiers

2013-001425-71

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ALX-0171-1.3/13

Identifier Type: -

Identifier Source: org_study_id